NASDAQ:CDXS Codexis Q1 2023 Earnings Report $2.30 -0.03 (-1.29%) As of 04/30/2025 04:00 PM Eastern Earnings HistoryForecast Codexis EPS ResultsActual EPS-$0.34Consensus EPS -$0.29Beat/MissMissed by -$0.05One Year Ago EPS-$0.13Codexis Revenue ResultsActual Revenue$12.98 millionExpected Revenue$14.09 millionBeat/MissMissed by -$1.11 millionYoY Revenue Growth-63.30%Codexis Announcement DetailsQuarterQ1 2023Date5/4/2023TimeAfter Market ClosesConference Call DateThursday, May 4, 2023Conference Call Time4:00PM ETUpcoming EarningsCodexis' Q1 2025 earnings is scheduled for Thursday, May 1, 2025Conference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Codexis Earnings HeadlinesCodexis to Report First Quarter 2025 Financial Results on May 14April 30 at 4:15 PM | globenewswire.comCodexis (CDXS) Projected to Post Quarterly Earnings on ThursdayApril 29 at 3:47 AM | americanbankingnews.comThe Worst Year in American Financial History?Economist Explains: The Curse on the U.S. Dollar Yes, there is a Curse on the U.S. Dollar... and it's behind all the chaos you've seen play out in the global economy in 2025. This curse has nothing to do with astrology or anything metaphorical. In fact, it's studied at the highest levels of finance and academia ... and VP Vance even questioned Jerome Powell about it. It's a wild money story you could soon hear everywhere. Only one investigative journalist is telling the story here.May 1, 2025 | Stansberry Research (Ad)Major Investment Alert: Opaleye Management Inc. Boosts Stake in Codexis!April 9, 2025 | tipranks.comCodexis Announces Board Member Retirement in April 2025April 9, 2025 | tipranks.comCodexis Announces Byron Dorgan to Retire from Board of DirectorsApril 9, 2025 | globenewswire.comSee More Codexis Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Codexis? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Codexis and other key companies, straight to your email. Email Address About CodexisCodexis (NASDAQ:CDXS) discovers, develops, and sells enzymes and other proteins. The company operates through two segments, Performance Enzymes and Novel Biotherapeutics. It offers biocatalyst products and services. The company also provides biocatalyst screening and protein engineering services. In addition, it offers CodeEvolver, a technology platform, which helps in developing and delivering biocatalysts that perform chemical transformations and enhance the efficiency and productivity of manufacturing processes. The company's platform is also used for molecular biology and in vitro diagnostic enzymes. It has a collaboration agreement with Nestlé Health Science to develop CDX-7108 for the treatment of exocrine pancreatic insufficiency. The company sells its products to pharmaceutical manufacturers through its direct sales and business development force in the United States and Europe. The company was incorporated in 2002 and is headquartered in Redwood City, California.View Codexis ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Earnings By Country U.S. Earnings Reports Canadian Earnings Reports U.K. Earnings Reports Latest Articles Amazon's Earnings Will Make or Break the Stock's Comeback CrowdStrike Stock Nears Record High, Dip Ahead of Earnings?Alphabet Rebounds After Strong Earnings and Buyback AnnouncementMarkets Think Robinhood Earnings Could Send the Stock UpIs the Floor in for Lam Research After Bullish Earnings?Texas Instruments: Earnings Beat, Upbeat Guidance Fuel RecoveryMarket Anticipation Builds: Joby Stock Climbs Ahead of Earnings Upcoming Earnings Airbnb (5/1/2025)Apple (5/1/2025)Amazon.com (5/1/2025)Amgen (5/1/2025)Linde (5/1/2025)MercadoLibre (5/1/2025)Monster Beverage (5/1/2025)Strategy (5/1/2025)Atlassian (5/1/2025)Arthur J. Gallagher & Co. (5/1/2025) Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
